Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Separating a Cancer Prevention Drug from Heart Disease Risk

14.09.2011
Highlights:
*Celecoxib reduces the risk of developing precancerous colon polyps, at the cost of increased heart disease risk.
*By looking closely at how celecoxib acts in the cell, it may be possible to get the benefit without the added risk.
*Celecoxib inhibits the enzyme GSK3, possibly accounting for its anticancer effects in multiple cell types.

Several clinical studies have shown that taking the anti-inflammatory drug celecoxib can reduce the risk of developing polyps that lead to colon cancers, at the cost of increasing the risk of heart disease. But what if this tradeoff was not necessary?

Researchers at Winship Cancer Institute of Emory University have identified a way that celecoxib (Celebrex) pushes cancer cells into suicide, separately from its known effects. The Winship team’s results outline a route to alternatives to celecoxib that keep its cancer-preventive properties while avoiding its risks.

Celecoxib’s risk profile has confined its use to people who have inherited cancer risk or those who have had cancer already. Its effectiveness at stopping tumor progression and recurrence is being tested in several clinical trials for people who have had lung, head and neck and other types of cancer.

Shi-Yong Sun, PhD, and colleagues report in an upcoming issue of the journal Cancer Research that celecoxib inhibits an enzyme called GSK3 (glycogen synthase kinase 3) in lung cancer cells. This causes the disappearance of a protein called c-FLIP, which usually staves off apoptosis, a form of cellular suicide.

“We have been focusing on how celecoxib induces c-FLIP degradation and apoptosis in cancer cells, independent of COX-2 inhibition,” Sun says.

Scientists think that celecoxib’s ability to inhibit COX-2 enzymes is the basis for its anti-inflammatory properties as well as its influence on heart disease. In cell culture, some chemical relatives of celecoxib have been shown to have anticancer effects without inhibiting COX-2.

Sun is professor of hematology and medical oncology at Emory University School of Medicine and a Georgia Cancer Coalition Distinguished Cancer Scholar. The first author of the paper, postdoc Shuzhen Chen, is now at the Chinese Academy of Medical Sciences’ Institute of Medicinal Biotechnology in Beijing. Fadlo Khuri, MD, deputy director of Winship Cancer Institute, is a co-author on the paper.

The result was surprising partly because until a few years ago, scientists thought that inhibiting GSK3, while possibly helpful in diseases such as diabetes, could promote cancer. However, recent results suggest that blocking GSK3 may stop cell growth in prostate, pancreatic and colon cancers and some types of leukemia.

Sun cautions: “We do not know whether GSK3 inhibition by celecoxib has anything to do with celecoxib’s cardiovascular risk.”

The research was supported by the Georgia Cancer Coalition, the Department of Defense and the National Institutes of Health.

S. Chen, W. Cao, P. Yue, C. Hao, F.R. Khuri and S.Y Sun. Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res. Online ahead of print. (2011).

The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focused on missions of teaching, research, health care and public service.

Learn more about Emory’s health sciences:
Blog: http://emoryhealthblog.com
Twitter: @emoryhealthsci
Web: http://emoryhealthsciences.org

Holly Korschun | EurekAlert!
Further information:
http://www.emory.edu

Further reports about: COX-2 Cancer Drug Delivery GSK3 Prevention Separating Winship cancer cells colon cancer heart disease

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>